Document:

<PAGE>
                                                                    Exhibit 10.6

                        ADDENDUM TO SUBLICENSE AGREEMENT

         THIS ADDENDUM to the Sublicense Agreement dated August 10, 2001 by and
between BioDelivery Sciences International, Inc. ("BDSI") and BioDelivery
Sciences, Inc. ("Agreement") and Tatton Technologies, LLC ("Tatton") is made and
entered into as of this 29th day of March 2002.

                              W I T N E S S E T H:

         WHEREAS, BioDelivery Sciences International, Inc., BioDelivery
Sciences, Inc. and Tatton entered into a Sublicense Agreement on August 10, 2001
which the parties wish to amend and modify as hereinafter set forth; and

         WHEREAS, BioDelivery Sciences, Inc. was subsequently merged into BDSI;
and

         WHEREAS, the parties wish to cause all royalty payments under this
Agreement to be calculated based upon Net Revenue as opposed to Net Profits in
order to eliminate the potential of regulatory, calculation, and accounting
concerns.

         NOW, THEREFORE, for good and valuable consideration in hand received,
including the mutual covenants and promises of the parties as set forth herein,
the parties mutually agree as follows:

         1. Paragraph 3 of the Sublicense Agreement of BDS into BDSI is hereby
deleted in its entirety and replaced with the following:

         "3. ROYALTY. Tatton agrees to pay BDSI a royalty equal to twelve
         percent (12%) of all net revenue (the "Net Revenue") received by Tatton
         from the sale of products which incorporate the BDSI Technology. For
         purposes hereof, Net Revenue, shall mean all revenue received by Tatton
         from the sale of products incorporating the BDSI Technology, less
         verifiable discounts. Net Revenue shall be computed in a consistent
         manner. Additionally, should Tatton enter into permitted licenses, as
         opposed to directly selling products incorporating the BDSI Technology,
         Tatton shall pay BDSI a royalty equal to thirty percent (30%) of all
         such royalties received by Tatton from the sublicensed products that
         include the BDSI Technology for permitted designated uses. Tatton shall
         not assign, sell, or otherwise sublicense its interest hereunder
         without the prior written consent of BDSI. Tatton shall pay all
         royalties hereunder on or before the 10th day of each month. All
         royalty payments shall be accompanied by a written report specifying
         revenues and discounts, and itemizing royalties received by Tatton
         relating to products which incorporate the BDSI Technology. BDSI shall
         have the right to inspect the books and records of Tatton at any
         reasonable time during normal business hours."

         2. All other terms and conditions of the Sublicense Agreement remain in
full force and effect.

         3. All references in this Addendum and in the Agreement to BioDelivery
Sciences, Inc. ("BDS") specifically mean and refer to BDSI subsequent to the
merger of BDS into BDSI.
<PAGE>
         IN WITNESS WHEREOF, the parties have set their hand and seal on the day
and year first above written.

BioDelivery Sciences International, Inc.         Tatton Technologies, LLC

By:     /s/ Raphael Mannino                      By:      /s/ Terry A. Fuller
     -----------------------------------            ----------------------------
     Raphael Mannino, PhD.                           Terry A. Fuller, PhD.
     Executive Vice President and                    President
     Chief Scientific Officer<PAGE>
                                                                    Exhibit 10.8

                        ADDENDUM TO SUBLICENSE AGREEMENT

         THIS ADDENDUM to the Sublicense Agreement dated August 10, 2001 by and
between BioDelivery Sciences International, Inc. ("BDSI") and BioDelivery
Sciences, Inc. ("Agreement") and RetinaPharma, Inc. ("RetinaPharma") is made and
entered into as of this 29th day of March 2002.

                              W I T N E S S E T H:

         WHEREAS, BioDelivery Sciences International, Inc., BioDelivery
Sciences, Inc. and RetinaPharma entered into a Sublicense Agreement on August
10, 2001 which the parties wish to amend and modify as hereinafter set forth;
and

         WHEREAS, BioDelivery Sciences, Inc. was subsequently merged into BDSI;
and

         WHEREAS, the parties wish to cause all royalty payments under this
Agreement to be calculated based upon Net Revenue as opposed to Net Profits in
order to eliminate the potential of regulatory, calculation, and accounting
concerns.

         NOW, THEREFORE, for good and valuable consideration in hand received,
including the mutual covenants and promises of the parties as set forth herein,
the parties mutually agree as follows:

         1. Paragraph 3 of the Sublicense Agreement of BDS into BDSI is hereby
deleted in its entirety and replaced with the following:

         "3. ROYALTY. RetinaPharma agrees to pay BDSI a royalty equal to twelve
         percent (12%) of all net revenue (the "Net Revenue") received by
         RetinaPharma from the sale of products which incorporate the BDSI
         Technology. For purposes hereof, Net Revenue, shall mean all revenue
         received by RetinaPharma from the sale of products incorporating the
         BDSI Technology, less verifiable discounts. Net Revenue shall be
         computed in a consistent manner. Additionally, should RetinaPharma
         enter into permitted licenses, as opposed to directly selling products
         incorporating the BDSI Technology, RetinaPharma shall pay BDSI a
         royalty equal to thirty percent (30%) of all such royalties received by
         RetinaPharma from the sublicensed products that include the BDSI
         Technology for permitted designated uses. RetinaPharma shall not
         assign, sell, or otherwise sublicense its interest hereunder without
         the prior written consent of BDSI. RetinaPharma shall pay all royalties
         hereunder on or before the 10th day of each month. All royalty payments
         shall be accompanied by a written report specifying revenues and
         discounts, and itemizing royalties received by RetinaPharma relating to
         products which incorporate the BDSI Technology. BDSI shall have the
         right to inspect the books and records of RetinaPharma at any
         reasonable time during normal business hours."

         2. All other terms and conditions of the Sublicense Agreement remain in
full force and effect.
<PAGE>
         3. All references in this Addendum and in the Agreement to BioDelivery
Sciences, Inc. ("BDS") specifically mean and refer to BDSI subsequent to the
merger of BDS into BDSI.

         IN WITNESS WHEREOF, the parties have set their hand and seal on the day
and year first above written.

BioDelivery Sciences International, Inc.          RetinaPharma, Inc.

By:     /s/ Raphael Mannino                       By:      /s/ Terry A. Fuller
     ----------------------------------------         --------------------------
      Raphael Mannino, PhD.                           Terry A. Fuller, PhD.
      Executive Vice President and                    Chief Executive Officer
      Chief Scientific Officer<PAGE>
                                                                   Exhibit 10.15

                              EMPLOYMENT AGREEMENT
                    BIODELIVERY SCIENCES INTERNATIONAL, INC.

         THIS EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of
this 29th day of March, 2002, by and between BioDelivery Sciences International,
Inc., an Indiana corporation, (the "Company") and Francis E. O'Donnell, MD
("Employee").

                                R E C I T A L S:

         WHEREAS, the Company is engaged in the business of developing and
commercializing proprietary and patented cochleate delivery technology;

         WHEREAS, the Company wishes to enter into this Employment Agreement
with Employee, to set forth and govern the terms, conditions and duties of
employment of Employee with the Company; and

         WHEREAS, the Company and the Employee are desirous of setting forth in
this definitive Employment Agreement their respective rights and obligations
with respect to Employee's employment with the Company.

         NOW, THEREFORE, in consideration of the mutual promises in this
Agreement and for additional good and valuable consideration, the receipt and
sufficiency of which is acknowledged by the parties hereto, the Company and the
Employee agree as follows:

         1. EMPLOYMENT AND TERM. On the terms and subject to the conditions of
this Agreement, the Company agrees to employ the Employee and the Employee
accepts such employment. This Agreement shall commence on the date hereof (the
"Commencement Date") and shall continue in effect for a period of three years
from the date hereof. This Agreement shall terminate at the end of said
three-year period (the "Termination Date") unless earlier terminated pursuant to
Paragraph 6 below.

         2. DUTIES. Beginning on the Commencement Date, Employee will be
employed by the Company to perform the duties as interim President and Chief
Executive Officer. During the term, Employee shall perform his duties and
responsibilities under this Agreement on a full-time basis. During the term of
this Agreement, Employee shall not be employed with any other entity. However,
Employee may serve as a director of other entities and may provide services
associated with his personal investments, provided such activities do not
interfere with the performance of his duties under this Agreement.

         3. COMPENSATION. During the Term of this Agreement, as compensation for
Employee performing the Duties, the Company shall pay Employee the compensation,
as set forth on Exhibit "A" which is attached hereto, incorporated herein and
made a part hereof ("Compensation").

         4. TERMINATION OF EMPLOYMENT. The term of this Agreement is two (2)
years; provided, however, that the Company may terminate this Agreement upon 30
days' written notice or upon the selection of a permanent President and Chief
Executive Officer.
<PAGE>
                                                                               2

         5. NON-COMPETITION. Simultaneously with his execution of this
Agreement, Employee shall execute a Covenant Not to Compete Agreement with the
Company, as set forth on Exhibit "B" which is attached hereto, incorporated
herein and made a part hereof.

         6. CONFIDENTIALITY/WAIVER OF INTEREST. Simultaneously with the
execution of this Agreement, Employee shall execute a Confidentiality/Waiver of
Interest Agreement with the Company, as set forth on Exhibit "C" which is
attached hereto, incorporated herein and made a part hereof and which shall be
effective from the date of execution.

         7. NOTICES. Any notice provided for in this Agreement must be in
writing and must be either personally delivered or mailed by certified mail,
return receipt required, to the recipient at the address indicated below:

<TABLE>
<CAPTION>
         TO THE COMPANY:                                               TO THE EMPLOYEE:
         <S>                                                           <C>
         BioDelivery Sciences International, Inc.                      Francis E. O'Donnell, MD
         Two Huntington Quadrangle                                     709 The Hamptons Lane
         Melville, New York 11747                                      Town & Country, MO 63017
</TABLE>

or such other address or to the attention of such other person as the recipient
party shall have specified by prior written notice to the sending party.

         8. SEVERABILITY. In the event that any provision of this Agreement
shall be held to be unreasonable, invalid, or unenforceable for any reason
whatsoever, the parties agree that: (i) such invalidity or unenforceability
shall not affect any other provision of this Agreement and the remaining
covenants, restrictions, and provisions hereof shall remain in full force and
effect; and (ii) any court of competent jurisdiction may so modify the
objectionable provision as to make it valid, reasonable, and enforceable, and
such provision, as so modified, shall be valid and binding as though the
invalid, unreasonable, or unenforceable portion thereof had not been included
therein.

         9. COMPLETE AGREEMENT. This Agreement contains the entire agreement of
the parties and supersedes and preempts any prior understandings, agreements or
representations between Employee and the Company regarding the employment of
Employee.

         10. COUNTERPARTS. This Agreement may be simultaneously executed in two
counterparts, each of which shall be an original, and all of which shall
constitute but one and the same instrument.

         11. CHOICE OF LAW. This Agreement shall be governed by and construed in
accordance with the laws of the state of Missouri.

         12. ATTORNEY'S FEES. In the event that either party to this Agreement
shall be forced to retain the services of any attorney to enforce any of the
provisions hereof, then the prevailing party in any ensuing litigation shall be
entitled to recover from the non-prevailing party the prevailing party's
reasonable attorney's fees, court costs or other expenses of litigation, whether
incurred at trial or upon appeal.
<PAGE>
                                                                               3

         13. AMENDMENTS/WAIVERS. This Agreement may only be modified, amended,
or waived by a writing duly authorized and executed by all parties.

         IN WITNESS WHEREOF, the parties have executed this Agreement on the day
and year first above written.

           THE COMPANY:                                    EMPLOYEE:
BioDelivery Sciences International, Inc.

By:    /s/ James A. McNulty                         /s/ Francis E. O'Donnell
    ---------------------------                 --------------------------------
    James A. McNulty  Its  CFO                          Francis E. O'Donnell
<PAGE>
                                                                               4

                                   EXHIBIT "A"

                              EMPLOYMENT AGREEMENT
                BETWEEN BIODELIVERY SCIENCES INTERNATIONAL, INC.
                                       AND
                            FRANCIS E. O'DONNELL, MD

         In accordance with Paragraph 3, Employee shall be paid the following
Compensation payable as set forth below:

         1.       $48,000 annual base salary, payable monthly.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}]]